1 UK stock to consider buying under 400p
With the FTSE 100 at a record high, it’s become a bit trickier to spot undervalued UK stocks. Therefore, it might be a good idea to look at unloved sectors, as many shares in these will be down by default. Babies being thrown out with the bath water, as it were.
Some unloved areas right now include renewable energy, small-caps, REITs, housebuilders, and retail stocks. There will undoubtedly be lucrative opportunities hiding in plain sight in these spaces.
For me though, one sector that looks undervalued from a long-term perspective is healthcare. This area’s been shunned for some time, due to uncertainty around tariffs on pharmaceutical imports into the US, as well as moves by President Trump to lower drug prices.
Consequently, valuations of big pharma firms are very low compared to historic norms. And I think this area could be a fruitful hunting ground for long-term investors.
A UK trust
Rather than picking individual healthcare stocks though, I think a smarter (and safer) way to consider investing would be through an investment trust or exchange-traded fund (ETF).
One I like is Polar Capital Global Healthcare Trust (LSE:PCGH). Established in 2007, this trust invests in what it sees as the best opportunities globally, across all healthcare subsectors. These range from innovative small-cap biotech stocks to global pharma giants.
The top two stocks are Eli Lilly and AstraZeneca, which are respectively enjoying solid growth from weight-loss drugs (particularly Mounjaro) and innovative cancer treatments. Both are world-class companies with strong long-term growth prospects.
Beyond pharma, the trust also has a lot of exposure to businesses supplying healthcare equipment and life sciences tools. Top names here include Thermo Fisher Scientific, Intuitive Surgical, and insulin delivery innovator Insulet.
While the sector’s struggled in recent years, Polar Capital Global Healthcare Trust’s done better. Over the last three years, it’s up about 23% to 390p, easily outperforming the wider healthcare market.
Uncertainty persists
As mentioned, there’s still uncertainty around tariffs in the US, though many large companies have announced significant investments in US manufacturing capacity in recent months.
As for US drug prices, this issue remains a risk because the details are still being ironed out. Reforms could result in lower profits for some drugmakers.
Two big trends
The pace of innovation in healthcare continues to accelerate, not just in respect of novel therapies, but also new devices are opening up new markets and technological advances are increasing efficiency… with valuations attractive, it is not unreasonable for healthcare investors to look ahead with a high degree of optimism.
Polar Capital Global Healthcare Trust.
Taking a longer-term view, I’m bullish on this sector for two reasons. First, the global population’s living longer. So this ageing factor should naturally drive more demand for healthcare provision.
Meanwhile, artificial intelligence (AI) is advancing rapidly. As the technology improves, it has the ability to massively accelerate and improve the drug-discovery process, potentially fattening profit margins across the whole industry.
Indeed, Nvidia CEO Jensen Huang has repeatedly said he thinks AI’s biggest impact will be in healthcare and drug discovery. Given his incredible record for envisioning future trends, I wouldn’t bet against this.
For investors, the good news is that none of this potential’s priced in today. Therefore, I reckon this UK healthcare trust’s worth examining.
The post 1 UK stock to consider buying under 400p appeared first on The Motley Fool UK.
Should you invest £1,000 in Polar Capital Global Healthcare Trust plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Polar Capital Global Healthcare Trust plc made the list?
More reading
- Is this penny share deep value hiding in plain sight?
- 7%+ yields: 3 FTSE dividend shares to consider this November
- Can the FTSE 100 smash through 10,000 points by Christmas?
- Hereâs how an ISA worth £20k today could generate £1,600 in passive income by next Halloween!
- How big does an ISA need to be to target £1,500 in monthly second income?
Ben McPoland has positions in AstraZeneca Plc, Intuitive Surgical, and Nvidia. The Motley Fool UK has recommended AstraZeneca Plc, Intuitive Surgical, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
